PATENT CLAIM ANALYSIS

Application Number: 15940250
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "009600"]

Abstract:
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Claim (Index 6):
The method of  claim 1 , wherein said peptide is recombinant human GGF2.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 90.0
- Lexical Diversity: 1.18
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14928124', '13904654', '13059206', '15357586', '12380760']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8339762006927961
- 35 USC 102 Novelty (BERT): 0.6421862520090997
- Combined Prediction Score: 0.8147972058244264
- Mean Citation Score: 508.706112
- Max Citation Score: 598.0687
- Similarity Product: 592.4395047536373

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test